TypeScript 7.0 is now stable after Microsoft ported the entire compiler to Go, delivering build-time speedups of 8x to 12x ...

The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...

Learning to program in C on an online platform can provide structured learning and a certification to show along with your resume. Learning C can still be useful in 2026, especially if you want to ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Abstract: Reconfigurable arrays enable flexible utilization of system resources, and thus become a key technology in modern radar and communication systems. Once the array is reconfigured, its ...

Abstract: Reconfigurable arrays enable flexible utilization of system resources and thus become a key technology in modern radar and communication systems. Once the array is reconfigured, its steering ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...